| Year |
Title |
Altmetric |
| 2017
|
The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.
Brain Stimulation.
10:651-656.
2017
|
|
| 2015
|
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Annals of Neurology.
78:248-257.
2015
|
|
| 2015
|
Spatial topographies of unilateral subthalamic nucleus deep brain stimulation efficacy for ipsilateral, contralateral, midline, and total Parkinson disease motor symptoms.
Neurosurgery.
11:80-88.
2015
|
|
| 2014
|
Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.
Journal of Applied Physiology.
116:582-592.
2014
|
|
| 2014
|
Effects of deep brain stimulation frequency on bradykinesia of Parkinson's disease.
Movement Disorders.
29:203-206.
2014
|
|
| 2014
|
A randomized clinical trial of high-dosage coenzyme Q10 in early parkinson disease no evidence of benefit.
JAMA Neurology.
75:543-552.
2014
|
|
| 2013
|
The relationship between clinical phenotype and early staged bilateral deep brain stimulation in Parkinson disease: Clinical article.
Journal of Neurosurgery.
119:1530-1536.
2013
|
|
| 2013
|
Impaired financial abilities in Parkinson's disease patients with mild cognitive impairment and dementia.
Parkinsonism and Related Disorders.
19:986-990.
2013
|
|
| 2012
|
Reliability of a new scale for essential tremor.
Movement Disorders.
27:1567-1569.
2012
|
|
| 2012
|
Short latency activation of cortex by clinically effective thalamic brain stimulation for tremor.
Movement Disorders.
27:1404-1412.
2012
|
|
| 2012
|
Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease.
Movement Disorders.
27:864-873.
2012
|
|
| 2012
|
High-frequency deep brain stimulation of the putamen improves bradykinesia in Parkinson's disease.
Movement Disorders.
27:168-169.
2012
|
|
| 2012
|
Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.
Parkinsonism and Related Disorders.
18:63-68.
2012
|
|
| 2011
|
High-frequency deep brain stimulation of the putamen improves bradykinesia in Parkinson's disease.
Movement Disorders.
26:2232-2238.
2011
|
|
| 2011
|
Comparison of weight changes following unilateral and staged bilateral STN DBS for advanced PD.
Brain and Behavior.
1:12-18.
2011
|
|
| 2011
|
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: A double-blind, randomised, controlled trial.
Lancet Neurology.
10:509-519.
2011
|
|
| 2011
|
Activation of subthalamic neurons by contralateral subthalamic deep brain stimulation in parkinson disease.
Journal of Neurophysiology.
105:1112-1121.
2011
|
|
| 2011
|
The effects of deep brain stimulation on sleep in Parkinson’s disease.
Therapeutic Advances in Neurological Disorders.
4:15-24.
2011
|
|
| 2010
|
Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial.
Lancet Neurology.
9:1164-1172.
2010
|
|
| 2010
|
A long-term study of istradefylline in subjects with fluctuating Parkinson's disease.
Parkinsonism and Related Disorders.
16:423-426.
2010
|
|
| 2010
|
Striatal overexpression of ΔFosB reproduces chronic levodopa-induced involuntary movements
2010
|
|
| 2010
|
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Movement Disorders.
25:858-866.
2010
|
|
| 2010
|
Construction of relational topographies from the quantitative measurements of functional deep brain stimulation using a 'roving window' interpolation algorithm.
Stereotactic and Functional Neurosurgery.
88:16-23.
2010
|
|
| 2010
|
Quality of life in parkinson's disease patients following adjunctive tolcapone therapy: Results of an open-label, multicenter, community-based trial
2010
|
|
| 2009
|
Relief of acquired stuttering associated with Parkinson's disease by unilateral left subthalamic brain stimulation.
Journal of Speech, Language, and Hearing Research.
52:1652-1657.
2009
|
|
| 2009
|
Weight changes associated with unilateral STN DBS and advanced PD.
Parkinsonism and Related Disorders.
15:709-711.
2009
|
|
| 2009
|
Bilateral effects of unilateral subthalamic deep brain stimulation on parkinson's disease at 1 year.
Neurosurgery.
65:302-309.
2009
|
|
| 2009
|
Liquid chromatography tandem mass spectrometry identification of proanthocyanidins in rat plasma after oral administration of grape seed extract.
Phytomedicine.
16:233-243.
2009
|
|
| 2009
|
The contribution of executive control on verbal-learning impairment in patients with Parkinson's disease with dementia and Alzheimer's disease.
Archives of Clinical Neuropsychology.
24:237-244.
2009
|
|
| 2008
|
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: The GenePD study.
BMC Medicine.
6.
2008
|
|
| 2008
|
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Alzheimer's and Dementia.
4:421-427.
2008
|
|
| 2008
|
Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia.
Movement Disorders.
23:1867-1874.
2008
|
|
| 2008
|
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study.
Movement Disorders.
23:1596-1601.
2008
|
|
| 2008
|
Replication of association between ELAVL4 and Parkinson disease: The Gene PD study.
Human Genetics.
124:95-99.
2008
|
|
| 2008
|
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study.
Neurology.
71:28-34.
2008
|
|
| 2008
|
Spheramine for Treatment of Parkinson's Disease.
Neurotherapeutics.
5:252-259.
2008
|
|
| 2008
|
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease.
Parkinsonism and Related Disorders.
14:77-80.
2008
|
|
| 2008
|
A pilot clinical trial of creatine and minocycline in early parkinson disease: 18-month results.
Clinical Neuropharmacology.
31:141-150.
2008
|
|
| 2008
|
Brain N-acetylaspartate is reduced in Parkinson disease with dementia.
Alzheimer Disease and Associated Disorders.
22:54-60.
2008
|
|
| 2007
|
Notice of redundant publication: "Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease" (Arch Neurol. 2007;64[5]:676-682). In reply [3].
JAMA Neurology.
64:1801.
2007
|
|
| 2007
|
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Movement Disorders.
22:2409-2417.
2007
|
|
| 2007
|
Erratum: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurology (2007) 68, (272-276)).
Neurology.
69:617.
2007
|
|
| 2007
|
Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease.
JAMA Neurology.
64:676-682.
2007
|
|
| 2007
|
Glutathione S-transferase polymorphisms and onset age in α-synuclein A53T mutant Parkinson's disease.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.
144:254-258.
2007
|
|
| 2007
|
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
Neurology.
68:20-28.
2007
|
|
| 2007
|
Corticobasal degeneration.
Handbook of Clinical Neurology.
84:351-372.
2007
|
|
| 2007
|
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Neurology.
68:272-276.
2007
|
|
| 2007
|
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurolgy (2007) 68, (272-276)).
Neurology.
69:2187.
2007
|
|
| 2007
|
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
Movement Disorders.
22:55-61.
2007
|
|
| 2006
|
Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD study.
Neurology.
67:2206-2210.
2006
|
|
| 2006
|
Report from a U.S. conference on essential tremor.
Movement Disorders.
21:2052-2061.
2006
|
|
| 2006
|
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
JAMA Neurology.
63:1250-1254.
2006
|
|
| 2006
|
Influence of heterozygosity for Parkin mutation on onset age in familial parkinson disease: The genePD study.
JAMA Neurology.
63:826-832.
2006
|
|
| 2006
|
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
Neurology.
66:664-671.
2006
|
|
| 2005
|
BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.
Neurology.
65:1823-1825.
2005
|
|
| 2005
|
Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease.
JAMA Neurology.
62:1833-1837.
2005
|
|
| 2005
|
Occupation and parkinsonism in three movement disorders clinics.
Neurology.
65:1430-1435.
2005
|
|
| 2005
|
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.
Movement Disorders.
20:1188-1191.
2005
|
|
| 2005
|
Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Sleep Medicine.
6:141-147.
2005
|
|
| 2004
|
Levodopa and the progression of parkinson’s disease.
New England Journal of Medicine.
351:2498-2508.
2004
|
|
| 2004
|
The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease.
Neurology.
63.
2004
|
|
| 2004
|
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
JAMA Neurology.
61:1563-1568.
2004
|
|
| 2004
|
Treatment of depression in Parkinson's disease.
Parkinsonism and Related Disorders.
10.
2004
|
|
| 2004
|
Erratum: Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease (Human Molecular Genetics (2003) vol. 12 (3259-3267)).
Human Molecular Genetics.
13:573.
2004
|
|
| 2004
|
Ophthalmologic features of Parkinson's disease.
Neurology.
62:177-180.
2004
|
|
| 2004
|
Implantation of Spheramine® in advanced Parkinson's Disease (PD).
Frontiers in Bioscience-Landmark.
9:592-602.
2004
|
|
| 2003
|
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.
Human Molecular Genetics.
12:3259-3267.
2003
|
|
| 2003
|
A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study.
Neurology.
61:1557-1561.
2003
|
|
| 2003
|
The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic [4].
JAMA Neurology.
60:1170-1173.
2003
|
|
| 2003
|
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.
JAMA Neurology.
60:975-980.
2003
|
|
| 2003
|
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Annals of Neurology.
54:93-101.
2003
|
|
| 2003
|
Benefits and risks of pharmacological treatments for essential tremor.
Drug Safety.
26:461-481.
2003
|
|
| 2003
|
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Annals of Neurology.
53:624-629.
2003
|
|
| 2003
|
Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.
Neurology.
60:1189-1191.
2003
|
|
| 2003
|
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.
American Journal of Human Genetics.
72:804-811.
2003
|
|
| 2003
|
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
Sleep Medicine.
4:275-280.
2003
|
|
| 2003
|
Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: A potential new cell therapy for Parkinson's disease.
Journal of neural transmission. Supplementum.
215-227.
2003
|
|
| 2002
|
Effects of coenzyme Q 10 in early Parkinson disease: Evidence of slowing of the functional decline.
JAMA Neurology.
59:1541-1550.
2002
|
|
| 2002
|
Depression associated with Parkinson's disease: Clinical features and treatment.
Neurology.
58.
2002
|
|
| 2002
|
Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD study.
Neurology.
58:79-84.
2002
|
|
| 2002
|
Age at onset in two common neurodegenerative diseases is genetically controlled.
American Journal of Human Genetics.
70:985-993.
2002
|
|
| 2002
|
PARK3 influences age at onset in Parkinson disease: A genome scan in the GenePD study.
American Journal of Human Genetics.
70:1089-1095.
2002
|
|
| 2001
|
Association of single-nucleotide polymorphisms of the tau gene with late-onset parkinson disease.
Journal of the American Medical Association.
286:2245-2250.
2001
|
|
| 2001
|
Complete genomic screen in parkinson disease evidence for multiple genes.
Journal of the American Medical Association.
286:2239-2244.
2001
|
|
| 2001
|
Genome-wide scan for Parkinson's disease: The GenePD study.
Neurology.
57:1124-1126.
2001
|
|
| 2001
|
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Movement Disorders.
16:858-866.
2001
|
|
| 2001
|
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines.
Neurology.
56.
2001
|
|
| 2001
|
Complications of gamma knife surgery for Parkinson disease.
JAMA Neurology.
58:1995-2002.
2001
|
|
| 2001
|
Corticobasal degeneration.
Seminars in Neurology.
21:49-58.
2001
|
|
| 2000
|
Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2β-carbo-1'-fluoro-2-propoxy-3β-(4-chlorophenyl)tropanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
Journal of Medicinal Chemistry.
43:639-648.
2000
|
|
| 1999
|
Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset.
Neurology.
53:1868-1870.
1999
|
|
| 1999
|
The α-synuclein gene is not a major risk factor in familial Parkinson disease [2].
Neurogenetics.
2:191-192.
1999
|
|
| 1999
|
Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates.
Experimental Brain Research.
125:397-409.
1999
|
|
| 1997
|
Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-dopa uptake and metabolism after intracerebral implantation in nonhuman primates.
Cell Transplantation.
6:469-477.
1997
|
|
| 1997
|
Corticobasal degeneration: Neuropathologic and clinical heterogeneity.
Neurology.
48:959-969.
1997
|
|
| 1997
|
Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: Two-year follow-up study.
Experimental Neurology.
147:510-517.
1997
|
|
| 1997
|
Fluorine-18-FPCT: A PET radiotracer for imaging dopamine transporters.
Journal of Nuclear Medicine.
38:119-126.
1997
|
|
| 1997
|
The role of dopamine agonists in early Parkinson's disease.
Neurology.
49.
1997
|
|
| 1996
|
Event-related potential P3 change in mild Parkinson's disease.
Movement Disorders.
11:32-42.
1996
|
|
| 1996
|
Cognitive estimation in patients with Alzheimer's disease.
Cognitive and Behavioral Neurology.
9:35-42.
1996
|
|
| 1996
|
Depression and disability in Parkinson's disease.
Journal of Neuropsychiatry and Clinical Neurosciences.
8:20-25.
1996
|
|
| 1995
|
Disruptive Nocturnal Behavior in Parkinson's Disease and Alzheimer's Disease.
Journal of Geriatric Psychiatry and Neurology.
8:107-110.
1995
|
|
| 1995
|
Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: Behavioral and anatomical assessment.
Cell Transplantation.
4:27-38.
1995
|
|
| 1994
|
Progressive supranuclear palsy: Neuropathologic and clinical heterogeneity.
Neurology.
44:1015-1024.
1994
|
|
| 1993
|
Mitochondrial dna variants observed in alzheimer disease and parkinson disease patients.
Genomics.
17:171-184.
1993
|
|
| 1992
|
Core assessment program for intracerebral transplantations (CAPIT).
Movement Disorders.
7:2-13.
1992
|
|
| 1992
|
Early Experience with Autologous Intrastriatal Adrenal Medulla/Nerve Cografting in Parkinson’s Disease.
Neural Plasticity.
3:272-273.
1992
|
|
| 1992
|
Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
Annals of Neurology.
32:113-114.
1992
|
|
| 1992
|
Quantifying Improvement Following CNS Transplantation in Hemiparkinsonian Monkeys Using Operant Behavioral Tasks.
Neural Plasticity.
3:238-239.
1992
|
|
| 1992
|
Reply.
Annals of Neurology.
32:227-227.
1992
|
|
| 1992
|
The role of motor cortex in the pathophysiology of voluntary movement deficits associated with parkinsonism.
Neurologic Clinics.
10:451-469.
1992
|
|
| 1991
|
Electrophysiologic analysis of early Parkinson's disease..
Geriatrics.
46 Suppl 1:31-36.
1991
|
|
| 1991
|
Autologous adrenal medulla-to-caudate grafting for Parkinsonism in humans and in nonhuman primates.
Frontiers in Neuroendocrinology.
12:357-378.
1991
|
|
| 1991
|
Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin a or basic fibroblast growth factor in ventricular fluid.
Experimental Neurology.
111:276-281.
1991
|
|
| 1991
|
Clozapine is beneficial for psychosis in parkinson's disease.
Neurology.
41:1699-1700.
1991
|
|
| 1991
|
Electrophysiologic analysis of early Parkinson’s disease.
Neurology.
41:44-48.
1991
|
|
| 1991
|
Mitochondrial oxidative phosphorylation defects in parkinson's disease.
Annals of Neurology.
30:332-339.
1991
|
|
| 1991
|
United parkinson foundation neurotransplantation registry on adrenal medullary transplants: Presurgical, and 1– and 2–year follow–up.
Neurology.
41:1719-1722.
1991
|
|
| 1990
|
Changes in Endocrine Function after Adrenal Medullary Transplantation to the Central Nervous System.
Journal of Clinical Endocrinology and Metabolism.
71:773-776.
1990
|
|
| 1990
|
Effect of adrenal-caudate transplantation on CSF levels of salsolinol sulfate in patients with Parkinson's disease..
Journal of neural transmission. Supplementum.
32:481-484.
1990
|
|
| 1990
|
Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status.
Journal of Neurology, Neurosurgery and Psychiatry.
53:279-283.
1990
|
|
| 1990
|
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Progress in Brain Research.
82:581-591.
1990
|
|
| 1990
|
Preliminary report on adrenal-brain transplantation for parkinsonism in man.
Stereotactic and Functional Neurosurgery.
54:312-323.
1990
|
|
| 1990
|
Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb.
Movement Disorders.
5:341-351.
1990
|
|
| 1989
|
Adrenal Medullary Autografts in Patients with Parkinson's Disease.
New England Journal of Medicine.
321:324-327.
1989
|
|
| 1988
|
Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease.
Neurology.
38:249-254.
1988
|
|
| 1986
|
Elastic properties of muscles measured at the elbow in man: I. normal controls.
Journal of Neurology, Neurosurgery and Psychiatry.
49:1171-1176.
1986
|
|
| 1986
|
Elastic properties of muscles measured at the elbow in man: II. Patients with Parkinsonian rigidity.
Journal of Neurology, Neurosurgery and Psychiatry.
49:1177-1181.
1986
|
|
